June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Genetic characteristics, genotype-phenotype correlation, and pilot treatment findings for Leber congenital amaurosis (LCA) in Taiwan
Author Affiliations & Notes
  • Ta-Ching Chen
    National Taiwan University, Taipei, Taiwan
  • Meng-Chieh Duh
    National Taiwan University, Taipei, Taiwan
  • Yu-Shu Huang
    National Taiwan University, Taipei, Taiwan
  • Yi-Chieh Chen
    National Taiwan University, Taipei, Taiwan
  • Chung-May Yang
    National Taiwan University, Taipei, Taiwan
  • Chang-Hao Yang
    National Taiwan University, Taipei, Taiwan
  • Jacob ShuJui Hsu
    National Taiwan University, Taipei, Taiwan
  • Pei-Lung Chen
    National Taiwan University, Taipei, Taiwan
  • Footnotes
    Commercial Relationships   Ta-Ching Chen None; Meng-Chieh Duh None; Yu-Shu Huang None; Yi-Chieh Chen None; Chung-May Yang None; Chang-Hao Yang None; Jacob ShuJui Hsu None; Pei-Lung Chen None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 401. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ta-Ching Chen, Meng-Chieh Duh, Yu-Shu Huang, Yi-Chieh Chen, Chung-May Yang, Chang-Hao Yang, Jacob ShuJui Hsu, Pei-Lung Chen; Genetic characteristics, genotype-phenotype correlation, and pilot treatment findings for Leber congenital amaurosis (LCA) in Taiwan. Invest. Ophthalmol. Vis. Sci. 2023;64(8):401.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Inherited retinal degeneration (IRD) is a leading cause of bilateral blindness in youth worldwide and Leber congenital amaurosis (LCA) is one of the most early-onset and visual-threatening subtypes. Recently, the development of gene therapy shed a light for these patients. Since 2015, our team launched Taiwan inherited retinal degeneration project (TIP) and has devoted to provide clinical service for patients of IRD in Taiwan from clinical diagnosis, molecular analysis, and novel therapies. Here, we reported the genetic characteristics, genotype-phenotype correlation, and pilot treatment findings for Leber congenital amaurosis (LCA) from TIP experience.

Methods : In TIP, 33 unrelated families (64 patients) of the 658 recruited IRD families from July 2015 to December 2021 were identified to have LCA. For each subject, a series of detailed ophthalmological examinations were performed including visual acuity, electroretinograms, fundus photography and autofluorescence imaging, and optical coherence tomography. Genomic DNA was extracted from peripheral blood samples and then sequenced by probe capture-based NGS approach of 233 IRD genes panel. The experimental methods and analysis pipeline for NGS data in this study was similar to our previous publication. (Chen et al., NPJ Genomic Medicine, 2021)

Results : Twenty-three of the 33 familes (69.7%) got genetic diagnosis through capture-based NGS panel and RDH12 (9), CRB1 (5), CEP290 (3), and RPE65 (2) are most common genotypes identified in our LCA cohort. Patients of RDH12-related LCA typically showed prominant central lesion with variable peripheral pigmentary changes and a large portion of patients had c.505C>G and/or c.806C>G variants. Most of our patients of CRB1- and CEP290-related LCA has milder macular but more prominant peripheral degeneration. Noteworthy, none of our CEP290-related patients in this cohort owned IVS26 mutation. One of our RPE65-related patient has flecks in mid-periphery and, to our surprise, the flecks largely diappeared 6 months after gene therapy bilaterally.

Conclusions : Here we reported our experience about genetic characteristics, genotype-phenotype correlation, and pilot treatment findings for Leber congenital amaurosis (LCA) in Taiwanese and hope this could help this field in clinical interpretation, genetic consultation, and future developement of gene therapy.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×